Skip to main content
. 2011 Jul;163(6):1263–1275. doi: 10.1111/j.1476-5381.2011.01310.x

Figure 5.

Figure 5

Proposed phase I and II biotransformation pathway for N-(4-hydroxyphenyl)retinamide (4-HPR). Potential pathways for the interconversion of one metabolite into another, that is, the conversion of N-(4-methoxyphenyl)retinamide (4-MPR) to 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), have been omitted due to the very low/no conversion kinetic parameters observed in HLM and MLM.